Eisai Company, Limited

Eisai R&d Management Co., Ltd.

The University of Tsukuka

Nobuhisa Watanabe

Hideyuki Adachi

Takao Saeki

Yasutaka Takase

Shigeru Souda

Hiroki Ishihara

Shuhei Miyazawa

Hironori Ikuta

Hitoshi Harada

Fumihiro Ozaki

Teiji Kimura

Kazuki Miyazaki

Tadashi Nagakura

Makoto Matsui

Kohtaro Kodama

Kenji Hayashi

Osamu Asano

Atsuhiko Kubota

Junichi Nagakawa

Yasuhiro Kabasawa

Hideaki Fujisaki

Kohtarou Kodama

Yasunori Akita

Tadakazu Tokumura

Hisatoshi Mochida

Toshihiko Kaneko

Masato Ueda

Tetsuya Kawahara

Kazutoshi Miyake

Masayuki Matsukura

Norio Karibe

Hiroshi Tanaka

Masanobu Shinoda

Itaru Tsukada

Keiji Ishibashi

Atsushi Kamada

Seiji Yoshikawa

Issei Ohtsuka

Yoshimitsu Naoe

Daisuke Iida

Hironobu Hiyoshi

Hiroki Terauchi

Shinya Abe

Shigeto Negi

Isao Saito

Naoyuki Shimomura

Seiichi Kobayashi

Keigo Tanaka

Yasushi Okamoto

Richard S Clark

Manabu Murakami

Tsutomu Kawata

Ichiro Yoshida

Takashi Inoue

Masashi Ito

Kozo Akasaka

Youji Yamagishi

Tadashi Okabe

Kiyoshi Oketani

Toshihiko Naito

Tohru Fujimori

Toshikazu Shimizu

Toshimi Okada

Nobuyuki Yasuda

Junsaku Nagaoka

Hiroshi Ishihara

Tatsuo Horizoe

Isao Tanaka

Toru Horie

Yoshiaki Ohashi

Noriyoshi Sakabe

Kimiyo Tabata

Daisuke Shinmyo

Motoji Kogushi

Nobuyuki Kurusu

Hiroko Kobayashi

Naoki Ozeki

Hiroe Minami

Koichi Nose

Kaya Ohashi

Atsushi Takemura

Mamoru Yanagimachi

Masahiro Sakurai

Toyokazu Haga

Yuji Onizawa

Motoji Kokushi

Toshie Yamada

Yasunobu Matsumoto

Mayu Shibazaki

Kotaro Kodama

Takashi Satoh

Hiroshi Akamatsu

Sachiko Kikuchi

A compound represented by formula (1) or a pharmaceutically acceptable salt thereof has an inhibitory effect in the fractalkine-CX3CR1 pathway: wherein R represents a Calkyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group A, a Ccycloalkyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group A, or a Ccycloalkenyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group A, X represents a Calkyl group, Y and Z are the same or different from each other and each represents a halogen atom or a Calkyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group B, n represents 0 or 1, Substituent Group A consists of halogen atoms, and Substituent Group B consists of halogen atoms.

Pyrrolidin-3-ylacetic acid derivative

A novel chemical compound useful as a therapeutic or prophylactic agent for acid-related diseases is provided, which has an excellent inhibitory effect against gastric acid secretion, an excellent effect of maintaining the inhibitory effect against gastric acid secretion, thereby maintaining intragastric pH high for a long time, and having more safety and appropriate physicochemical stability. Provided is a compound represented by where Rand Rmay be the same or different and each represent a hydrogen atom or a C1-C6 alkyl group; Rrepresents (5,5-dimethyl-1,3-dioxan-2-yl)methoxy group, 5,7-dioxaspiro[2.5]oct-6-ylmethoxy group, 1,5,9-trioxaspiro[5.5]undec-3-ylmethoxy group, or (2,2-dimethyl-1,3-dioxan-5-yl)methoxy group; R, R, Rand Rrepresent a hydrogen atom, halogen atom, C1-C6 alkyl group, C1-C6 haloalkyl group, C1-C6 alkoxy group or C1-C6 haloalkoxy group; and Wrepresents a single bond, methylene or ethylene group, a salt thereof or a solvate of these.

Benzimidazole compound

A compound represented by the following general formula (1), or a salt thereof has serine protease inhibiting activity, and particularly excellent inhibiting activity against clotting factor VIIa. This compound or a salt thereof is useful as therapeutic and/or prophylactic agents for diseases associated with thrombus formation. [wherein Rrepresents hydrogen, Rrepresents optionally substituted phenyl, etc., Rrepresents optionally substituted C6-10 aryl, etc.].

2,3-dihydro-iminoisoindole derivatives

A compound represented by the following general formula (1), or a salt or hydrate thereof: [Formula 1] wherein Rrepresents a C1-C6 alkyl group or C2-C6 alkynyl group which may be substituted, or a phenyl group which may be substituted, Rrepresents a hydrogen atom or a C1-C6 alkyl group, Rrepresents methyl or ethyl group, Rrepresents a C1-C6 alkyl group, Rrepresents a hydrogen atom, provided that a compound wherein Ris a C1-C6 alkyl group unsubstituted or substituted with a halogen atom and Ris a hydrogen atom is excluded.

Imidazopyridine compound

An object of the present invention is to provide a novel chemical compound useful as a therapeutic or prophylactic agent for acid-related diseases, having an excellent inhibitory effect against gastric acid secretion, an excellent effect of maintaining the inhibitory effect against gastric acid secretion, thereby maintaining intragastric pH high for a long time, and having more safety and appropriate physicochemical stability. Provided is a compound represented by 

An excellent squalene synthase inhibitor is provided. Specifically, what is provided is a compound (I) represented by the following formula, a salt thereof or a hydrate of them. In formula (I), Rrepresents an optionally substituted vinyl group or an aromatic ring which may be substituted. Also, n is an integer of 0 to 2. Further, X, Y and Z are the same as or different from each other and each represents an optionally substituted carbon atom, or an optionally substituted nitrogen atom, sulfur atom or oxygen atom, and Y optionally represents a single bond, and when Y represents the single bond, the ring to which X, Y and Z belong is a 5-membered ring. Also in the formula, CyA represents a 5- to 14 membered non-aromatic cyclic amino group or non-aromatic cyclic amido group which may be substituted, and the non-aromatic cyclic amino group or the non-aromatic cyclic amido group optionally having an oxygen atom or a sulfur atom. Finally, W represents a chain 

N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient

Amidino derivatives represented by the following general formula (I):{where X is a group represented by RSONR&#x2014; (wherein Rrepresents optionally substituted Caryl, etc. and Rrepresents hydrogen atom, etc.), etc., Arrepresents 2,6-naphthylene, etc., Rrepresents hydrogen atom, etc. and Y represents carboxyphenyl, etc.}and their pharmacologically acceptable salts or solvates.

Amidino derivatives and anticoagulants and thrombosis therapeutic agents containing them

The present invention provides a preventive or therapeutic agent for diabetes mellitus and diabetic complications, which is a new type based on an adenosine A2 receptor antagonist action. That is, it provides a novel condensed imidazole compound which has an adenosine A2 receptor antagonist action, is effective for preventing or treating diabetes mellitus and diabetic complications, and is represented by the formula (I);(wherein Rrepresents e.g. an amino group which may be substituted with an alkyl group; Rrepresents e.g. hydrogen atom, an alkyl group, a cycloalkyl group or an alkyl group, alkenyl group or alkynyl group which may be substituted with hydrox etc.; Rrepresents e.g. an optionally substituted alkyl group, alkenyl group, alkynyl group, aryl group, heteroaryl group, pyridinone group, pyrimidinone group or piperadinone group; Ar represents e.g. an optionally substituted aryl or heteroaryl group; and Q and W are the same as or different from each other and each represents N or CH), a pharmacologically acceptable salt or hydrates thereof.

Condensed imidazole compounds and a therapeutic agent for diabetes mellitus

Phthalazine compounds and therapeutic agents for erectile dysfunction

Phthalazine derivatives and remedies for erectile dysfunction

The present invnetion provides a remedy for erectile dysfunction. The active ingredient thereof is a fused pyridazine compound represented by the following formula (I) or a pharmacologically acceptable salt thereof:

Remedy for erection failure comprising fused pyridazine compound

A base member obtained by cutting a cylindrical body having a center axial line at a maximum asymmetric angle &agr;,with respect to a plane orthogonal to the center axial line of cylindrical body is prepared. Next, the thus obtained ellipsoidal asymmetric cut surface of the base member is shaped along a peripheral surface of an imaginary cylindrical body having a radius R,, into an asymmetric cut curved-surface. Then, a monochromator Si crystal is bonded to the asymmetric cut curved-surface of the base member. Both the asymmetric angle and the radius of curvature for a desired wavelength within a wide wavelength range can be simultaneously tuned only by the &phgr;-axis rotation.

Monochromator and method of manufacturing the same

Fused pyridazine compounds

The present invention provides a nitrogenous heterocyclic compound represented by the following general formula (1) or a pharmacologically acceptable salt thereof which is useful for various ischemic heart diseases and the like: ##STR1## �in formula (1), ring A represents a benzene ring, a pyridine ring or a cyclohexane ring; ring B represents a pyridine ring, a pyrimidine ring or an imidazole ring, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 represent each a hydrogen atom, a halogen atom or a group such as a lower alkoxy group; R.sup.5 represents a group represented by the formula --NR.sup.11 R.sup.12 (wherein R.sup.11 and R.sup.12 represent each a hydrogen atom or a group such as a lower alkyl group) or the like; and R.sup.6 represents a group represented by the formula ##STR2## (wherein R.sup.19 represents a hydrogen atom, a lower alkyl group or the like; R.sup.20, R.sup.21 and R.sup.22 represent each a hydrogen atom, a halogen atom, a hydroxyl group or the like; and r represents 0 or an integer of 1 to 8)!.

Quinazoline derivatives

Growing community of inventors

Tsukuba, Japan

Nobuhisa Watanabe